A critical need exists for a robust supply of clinician scientists trained in clinical pharmacology, a discipline ideally suited to our nation's current efforts to augment the translation of new and effective therapies into clinical practice. This application seeks to continue an established program that has a track record of excellence in training successful translational clinician scientists. The program has grown in depth and quality over the last funding period. The addition of new faculty has made possible an increase in the depth of programming and has continued a strong emphasis on minority recruitment. The established program excellence in drug disposition and pharmacogenomics has been augmented with deeper didactic training in drug development. A core faculty of 13, selected on the basis of quality research related to clinical pharmacology, peer-reviewed funding and training success and 32 supporting faculty now allow this program to serve as a central pillar within the institution's clinical research enterprise. The program contributes to a wide range of peer-reviewed research and is the key to NIH K-30 Clinical Investigator training program. The core faculty has funded research programs in cancer, cardiovascular, gastrointestinal, pediatric, obstetric and geriatric clinical pharmacology, as well as drug-induced liver disease, drug metabolism and disposition, drug interactions, pharmacogenetics and pharmacogenomics, ethics in therapeutic research and therapeutic outcomes. Trainees attend weekly journal clubs, clinical pharmacology seminars, clinical case conferences, and an organized weekly didactic program that runs year round in a two year cycle. In depth didactic training now concentrates on pharmacokinetics, pharmacogenomics, drug development, individualized therapeutics, and clinical trial design. Trainees may also elect to participate in the Indiana University Master of Science in Clinical Investigation. The core faculty selects trainees for the 2 to 3 year program based on their potential as clinician scientists from candidates with M.D. or M.D./ Ph.D. degrees and sufficient clinical training for primary specialty certification Exceptional candidates with Ph.D. or Pharm.D. degree's in areas related to the objectives of the program have be selected. Since first funded in 1992, qualified applicants have filled the training grant slots, and additional trainees have been funded from other sources. The program has generated stably funded academic physician scientists and leaders in the pharmaceutical industry and continues to serve a national role in training clinical pharmacologists.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Institutional National Research Service Award (T32)
Project #
5T32GM008425-19
Application #
8101952
Study Section
Special Emphasis Panel (ZGM1-BRT-5 (PG))
Program Officer
Okita, Richard T
Project Start
1992-07-01
Project End
2013-06-30
Budget Start
2011-07-01
Budget End
2012-06-30
Support Year
19
Fiscal Year
2011
Total Cost
$177,924
Indirect Cost
Name
Indiana University-Purdue University at Indianapolis
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
603007902
City
Indianapolis
State
IN
Country
United States
Zip Code
46202
Burgess, Kimberly S; Ipe, Joseph; Swart, Marelize et al. (2017) Variants in the CYP2B6 3'UTR Alter In Vitro and In Vivo CYP2B6 Activity: Potential Role of MicroRNAs. Clin Pharmacol Ther :
Hertz, Daniel L; Speth, Kelly A; Kidwell, Kelley M et al. (2017) Variable aromatase inhibitor plasma concentrations do not correlate with circulating estrogen concentrations in post-menopausal breast cancer patients. Breast Cancer Res Treat 165:659-668
Pierson, Rebecca C; Gufford, Brandon T; Desta, Zeruesenay et al. (2017) Clinical and educational impact of pharmacogenomics testing: a case series from the INGENIOUS trial. Pharmacogenomics 18:835-841
Robarge, Jason D; Metzger, Ingrid F; Lu, Jessica et al. (2017) Population Pharmacokinetic Modeling To Estimate the Contributions of Genetic and Nongenetic Factors to Efavirenz Disposition. Antimicrob Agents Chemother 61:
Towns, Rachel; Quinney, Sara K; Pierson, Rebecca C et al. (2017) Survey of Provider Preferences Regarding the Route of Misoprostol for Induction of Labor at Term. AJP Rep 7:e158-e162
Kadakia, Kunal C; Kidwell, Kelley M; Seewald, Nicholas J et al. (2017) Prospective assessment of patient-reported outcomes and estradiol and drug concentrations in patients experiencing toxicity from adjuvant aromatase inhibitors. Breast Cancer Res Treat 164:411-419
Gufford, B T; Ainslie, G R; White Jr, J R et al. (2017) Comparison of a New Intranasal Naloxone Formulation to Intramuscular Naloxone: Results from Hypothesis-generating Small Clinical Studies. Clin Transl Sci 10:380-386
Hertz, D L; Kidwell, K M; Seewald, N J et al. (2017) Polymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in postmenopausal patients with breast cancer. Pharmacogenomics J 17:521-527
Eadon, M T; Desta, Z; Levy, K D et al. (2016) Implementation of a pharmacogenomics consult service to support the INGENIOUS trial. Clin Pharmacol Ther 100:63-6
Cho, Doo-Yeoun; Shen, Joan H Q; Lemler, Suzanne M et al. (2016) Rifampin enhances cytochrome P450 (CYP) 2B6-mediated efavirenz 8-hydroxylation in healthy volunteers. Drug Metab Pharmacokinet 31:107-16

Showing the most recent 10 out of 110 publications